Latest News

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
11/28/16AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain
New speakers are: - Dr. Nathaniel Katz, CEO of Analgesic Solutions; Regulatory and Clinical Pain Expert - Dr. David Leiman, President of AIPM of Houston and Director of HD Research Corp.; Anesthesiologist and Principle Investigator REDWOOD CITY, Calif., Nov. 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, has announced an upda... 
Printer Friendly Version
11/17/16AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting
REDWOOD CITY, Calif., Nov. 17, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming presentation at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA). The presentation is part of the Emerging Technology Moderated Poster session and will mark the... 
Printer Friendly Version
11/09/16AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016
- Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain REDWOOD CITY, Calif., Nov. 9, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will host an Analyst & Investor Event... 
Printer Friendly Version
11/08/16AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in November
REDWOOD CITY, Calif., Nov. 8, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that senior management will be participating at the Global Mizuho Investor Conference, the Jefferies London Healthcare Conference and Piper Jaffray Healthcare Conference. Details of the events are as follows: Global... 
Printer Friendly Version
11/01/16AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016 Financial Results
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and nine months ended September 30, 2016.     Corporate Highlights ARX-04 Clinical and Commercial Update: During the third quarter of 2016, AcelRx presented the res... 
Printer Friendly Version
10/31/16AcelRx Pharmaceuticals to Present ARX-04 Analysis for Treatment of Moderate-to-Severe Acute Pain in Obese Patients at The Obesity Society Annual Meeting
REDWOOD CITY, Calif., Oct. 31, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming poster presentation at The Obesity Society Annual Meeting, which is taking place October 31 - November 4, 2016 in New Orleans, LA.   This poster presents data that shows that obese patients treated with ARX-04 (sufenta... 
Printer Friendly Version
10/25/16AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Tuesday, November 1st, 2016
REDWOOD CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Third Quarter financial results after market close on Tuesday, November 1st, 2016. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on November 1st, 2016 to... 
Printer Friendly Version
10/24/16AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings at National Conference on Correctional Health Care
REDWOOD CITY, Calif., Oct. 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming poster presentation at the 40th annual National Conference on Correctional Health Care, which summarizes findings from the Phase 3 SAP302 study of ARX-04 (sufentanil sublingual tablet, 30 mcg) in patients who were admitte... 
Printer Friendly Version
09/28/16AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine
REDWOOD CITY, Calif., Sept. 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine (ECEM), which is being held October 1-5, 2016 in Vienna, Austria. Both e-posters will be displayed on monitors ... 
Printer Friendly Version
09/27/16AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain
REDWOOD CITY, Calif., Sept. 27, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the initiation of the Phase 3 IAP312 study of Zalviso® (sufentanil sublingual tablet system), an investigational product candidate being developed for the management of moderate-to-severe acute pain in adult patients in a hosp... 
Printer Friendly Version
09/22/16Findings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting
REDWOOD CITY, Calif., Sept. 22, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Dr. Shankar Lakshman, a board-certified plastic surgeon and AcelRx clinical investigator, will present a subgroup analysis from the SAP301 study at the annual meeting of the American Society of Plastic Surgeons (ASPS). SA... 
Printer Friendly Version
09/22/16AcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
REDWOOD CITY, Calif., Sept. 22, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Howie Rosen, chief executive officer, will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference. Details of the event are as follows: Ladenburg Thalmann 2016 Healthcare Conference Date: Tuesday, Septembe... 
Printer Friendly Version
09/15/16AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303
- Majority of Patients Had No Adverse Event; Similar Across All Subgroups - Pain Intensity Was Reduced by 27% at 1 Hour, 49% at 2 Hours, 57% at 12 Hours - Phase 3 Program Now Complete; AcelRx Intends to Submit ARX-04 NDA This Year REDWOOD CITY, Calif., Sept. 15, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that in an open-label Phase 3 trial (SAP303), investigational product candidate ARX-04 (sufentanil sublingual tablet 30 mcg) was well tolerated in ... 
Printer Friendly Version
09/14/16AcelRx Pharmaceuticals to Announce Topline Results in Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
Management to host conference call tomorrow at 9:00 a.m. ET (6:00 a.m. PT) Thursday, September 15th REDWOOD CITY, Calif., Sept. 14, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, will announce the results of its multicenter, open-label Phase 3 clinical study of ARX-04, known as SAP303. The study was conducted in patients 40 years and ol... 
Printer Friendly Version
08/31/16AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
REDWOOD CITY, Calif., Aug. 31, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Timothy E. Morris, chief financial officer will be presenting at the BioCentury 23rd Annual NewsMakers Conference and the Rodman & Renshaw 18th Annual Global Investment Conference. Details of the events are as follows: BioCentury 23rd... 
Printer Friendly Version
08/29/16AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries
REDWOOD CITY, Calif., Aug. 29, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil sublingual tablet, 30 mcg) in 76 patients who were treated for moderate-to-severe acute pain in the emergency department. An oral presentation reviewing these results, including the types of injuries that were sustained by patients in the study, will be made at the Inte... 
Printer Friendly Version
08/15/16AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain
- Topline SAP302 Results Presented at Military Health System Research Symposium - REDWOOD CITY, Calif., Aug. 15, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported topline results from the single-arm, open-label Phase 3 SAP302 trial (NCT02447848), which assessed ARX-04 (sufentanil sublingual tablet, 30 mcg) in p... 
Printer Friendly Version
08/01/16AcelRx Pharmaceuticals to Present Initial Results of Phase 3 Study of ARX‑04 at World Congress of Mountain & Wilderness Medicine
REDWOOD CITY, Calif., Aug 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting top-line results from the initial cohort of 40 patients in single-arm, open-label Phase 3 SAP302 study, which assessed ARX-04 (sufentanil sublingual tablet, 30 mcg) as a treatment for moderate-to-severe acute pain in adults who presented to the emergency department with trauma or injury. These data will be presented at the 7th Wor... 
Printer Friendly Version
07/28/16AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results
REDWOOD CITY, Calif., July 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a corporate update and reported financial results for the three and six months ended June 30, 2016.     Corporate Highlights ARX-04 Clinical and Commercial Update: AcelRx completed enrollment in two Phase 3 studies: SAP302, wh... 
Printer Friendly Version
07/26/16AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, July 28th, 2016
REDWOOD CITY, Calif., July 26, 2016 /PRNewswire/-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Second Quarter financial results after market close on Thursday, July 28th, 2016. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on July 28th, 2016 to disc... 
Printer Friendly Version
07/06/16AcelRx Pharmaceuticals to Present at Cantor Fitzgerald 2nd Annual Healthcare Conference
REDWOOD CITY, Calif., July 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Executive Officer, Howard Rosen will be presenting at the Cantor Fitzgerald 2nd Annual Healthcare Conference. Details of the conference are as follows: Cantor Fitzgerald 2nd Annual Healthcare Conference Date: Tuesday, July 12 ... 
Printer Friendly Version
06/28/16AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain
- Top-line results expected in Q3 2016 - REDWOOD CITY, Calif., June 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it has completed patient enrollment in the two remaining Phase 3 studies of ARX-04 (sufentanil sublingual tablet, 30 mcg): SAP302 is a single-arm, open-label study that enrolled 7... 
Printer Friendly Version
06/27/16AcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes
REDWOOD CITY, Calif., June 27, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company has joined the broad-market Russell 3000 and Russell 2000 Indexes according to the final membership lists posted June 24th, 2016. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity mar... 
Printer Friendly Version
06/02/16AcelRx Pharmaceuticals to Participate in Three Upcoming Healthcare Investor Events in June
REDWOOD CITY, Calif., June 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at the Jefferies 2016 Healthcare Conference, 2016 BIO International Convention and participating in the 3rd Annual ROTH Healthcare Day. Details of the events are as follows: Jefferies 2016 Healthcare... 
Printer Friendly Version
05/26/16AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 following Ambulatory Abdominal Surgeries at Euroanaesthesia
REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is taking place in London, UK on May 28-30, 2016. In the SAP301 study, patients with moderate-to-severe acute pain following abdominoplasty, hernioplasty or laparoscopic abdominal surgeries were randomized to receive either ARX-04 (sufentanil sublingual 30 mcg tablet) or... 
Printer Friendly Version
05/24/16New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140
Results to be Presented at the 21st ISPOR Annual International Meeting REDWOOD CITY, Calif., May 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department for the treatment of acute pain. Based on an analysis of over 7 million patients who received IV opioids in 614 US emergency departments, it was found that the cost of administering an initial IV opioi... 
Printer Friendly Version
05/06/16AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type of Abdominal Surgery
REDWOOD CITY, Calif., May 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting a subgroup analysis of the Phase 3 SAP301 study results by surgery type (abdominoplasty, hernioplasty and laparoscopic abdominal surgery). SAP301 was a Phase 3 trial comparing ARX-04 (sufentanil sublingual 30 mcg tablet) to a placebo sublingual tablet in 163 patients with moderate-to-severe acute pain following ambulatory abdomina... 
Printer Friendly Version
05/04/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May
REDWOOD CITY, Calif., May 4, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at BioEquity Europe Conference 2016 and Bank of America Merrill Lynch 2016 Health Care Conference. BioEquity Europe Conference 2016 Date: Wednesday, May 11 Location: Scandic Hotel, Copenhagen Presenta... 
Printer Friendly Version
05/02/16AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
REDWOOD CITY, Calif., May 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three months ended March 31, 2016.     Corporate Highlights ARX-04 Emergency Room and Postoperative Studies: AcelRx initiated two Phase 3 studies in the first quarter of 201... 
Printer Friendly Version
04/28/16AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016
REDWOOD CITY, Calif., April 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release First Quarter financial results after market close on Monday, May 2nd, 2016. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 2nd, 2016 to discuss t... 
Printer Friendly Version
03/29/16AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
Conference call update at 4:30pm ET today REDWOOD CITY, Calif., March 29, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015.  Mr. Ro... 
Printer Friendly Version
03/25/16AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics
- Zalviso Clinical Program Highlighted in Publication in Hospital Pharmacy - REDWOOD CITY, Calif., March 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported that a review article entitled "Evolution of Patient-Controlled Analgesia: From Intravenous to Sublingual Treatment" has been published in the peer-revie... 
Printer Friendly Version
03/14/16AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
REDWOOD CITY, Calif., March 14, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced the initiation of the extension phase of the SAP302 study of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. This ongoing open-label P... 
Printer Friendly Version
03/07/16AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results
REDWOOD CITY, Calif., March 7, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and twelve months ended December 31, 2015.     Corporate Update and 2016 Objectives ARX-04 ER and Postoperative Studies: In December 2015, AcelRx, along with represen... 
Printer Friendly Version
03/07/16AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., March 7, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today that patient enrollment and dosing in a multicenter, open-label Phase 3 clinical study, known as SAP303, has been initiated. SAP303 is being conducted in patients 40 years and older who have moderate-to-severe acute pain follow... 
Printer Friendly Version
03/03/16AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016.
REDWOOD CITY, Calif., March 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release fourth quarter and yearly 2015 financial results after market close on Monday, March 7th, 2016. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 7... 
Printer Friendly Version
03/01/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March
REDWOOD CITY, Calif., March 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at the 36th Annual Health Care Conference in Boston and the 28th Annual ROTH Conference in Orange County. Details of the conferences are as follows: 36th Annual Health Care Conference Date:  Wednesday... 
Printer Friendly Version
02/25/16AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis
REDWOOD CITY, Calif., Feb. 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today reported encouraging interim efficacy and safety results of the ongoing single-arm, open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain asso... 
Printer Friendly Version
02/11/16AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium
REDWOOD CITY, Calif., Feb. 11, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a podium presentation will be made at the 38th annual John A. Boswick, M.D. Burn and Wound Care Symposium, which is being held February 14-18, 2016 in Hawaii. This international conference covers the latest advancements in wound healing, burn care, and infection control, and is endorsed by the American Burn Association, Australian-New Zealand Burns Association, Academy of Physicia... 
Printer Friendly Version
02/03/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February
REDWOOD CITY, Calif., Feb. 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer and Head of Business Development, Timothy E. Morris will be presenting at the 18th Annual BIO CEO & Investor Conference and the 2016 RBC Capital Markets' Healthcare Conference in New York. Details of the conference... 
Printer Friendly Version
01/21/16AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery
Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif., Jan. 21, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European Congress of Ambulatory Surgery to be held January 28th and 29th, 2016 at the Disneyland Hotel New York Convention Centre in Paris, France.  This bilingual congress (simultaneous translation will be provided)... 
Printer Friendly Version
01/10/16AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
- ARX-04 ER and Postoperative Study Results, NDA Submission - Initiation and Completion of Final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission - Zalviso™ Commercial Launch in the European Union REDWOOD CITY, Calif., Jan. 10, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced anticipated 2016 milestones for i... 
Printer Friendly Version
01/08/16AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso™ in 1Q 2016
REDWOOD CITY, Calif., Jan. 8, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported that the Company has received comments from the Division of Anesthesia, Analgesia, and Addiction Products (Division) of the U.S. Food and Drug Administration (FDA) on the Company's proposed protocol for a Phase 3 clinical study (IAP312) d... 
Printer Friendly Version